Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 /C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference